Table 1.
Demographic and baseline characteristics at anti- tumour necrosis factor [TNF] monotherapy initiation.
| Parameter | N = 350 |
|---|---|
| Age | 35.2 [23.7;43.9] |
| Gender [male] | 44.3% [155] |
| Active smoker | 54.9% [162] |
| Duration of disease [years] | 4.4 [1.5;12.1] |
| Number line of biological therapy | |
| •1st line | 68.6% [240] |
| •2nd line | 29.1% [102] |
| •3rd line | 2.0% [7] |
| •4th line | 0.3% [1] |
| Age at diagnosis [years]a | |
| •< 16 | 13.9% [47] |
| •17–40 | 68.7% [233] |
| •> 40 | 17.4% [59] |
| Localisation of diseasea | |
| •Ileum: L1 | 36.6% [123] |
| •Colon: L2 | 20.3% [70] |
| •Ileocolon: L3 | 43.0% [148] |
| Behavioura | |
| •Pure inflammatory: B1 | 57.7% [195] |
| •Stricturing: B2 | 25.1% [85] |
| •Penetrating: B3 | 17.2% [58] |
| Perianal disease | 39.0% [137] |
| Previous intestinal resection | 33.1% [115] |
| Concomitant medications | |
| •Oral 5-ASA | 9.8% [34] |
| •Budesonide | 8.7% [30] |
| •Systemic [oral or intravenous] steroids | 23.3% [81] |
| •Ciclosporin | 1.1% [4] |
| Indication of anti-TNF monotherapy initiation | |
| •Complicated behaviour | 34.6% [121] |
| •Flare | 13.1% [46] |
| •Fistula | 19.4% [68] |
| •Stenosis | 15.1% [53] |
| •Prophylaxis | 8.3% [29] |
| •Manifestation extra-digestive | 7.7% [27] |
| •Steroid-dependent disease | 16.9% [59] |
| •Steroid-refractory disease | 14.0% [49] |
| •Immunosuppressicve therapy failure | 26.3% [92] |
| •Failure of a first anti-TNF therapy | 12.6% [44] |
Results are expressed as median [interquartile range] for quantitative parameters and as percentage [frequency] for qualitative parameters.
5-ASA, 5-aminosalicylic acid.
aAccording to the Montreal classification